Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C

American Journal of Clinical Pathology

Volumn 130, Issue 5, 2008, Pages 796-804

  Herskovits, Adrianna Z ^a   Lemire, Susan J ^a   Longtine, Janina ^a   Dorfman, David M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Activated partial thromboplastin time; Activated protein C resistance; Economic evaluation; Factor V Leiden; Hereditary thrombophilia; Russell viper venom; Screening assays

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; VIPER VENOM; BLOOD CLOTTING FACTOR 5;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL LABORATORY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA; THROMBOSIS; ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ECONOMICS; GENETICS; LABORATORY DIAGNOSIS; METHODOLOGY; MIDDLE AGED; PROTHROMBIN TIME;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FACTOR V; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY;

EID: 55249102903     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP7YBJ6URTVCWP     Document Type: Article

References (22)

1. Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost. 2007;98:530-542.
2. Soria JM, Fontcuberta J. New approaches and future prospects for evaluating genetic risk of thrombosis. Haematologica. 2005;90:1212-1222.
3. Henry JB. Clinical Diagnosis and Management by Laboratory Methods. Philadelphia, PA: Saunders; 2001.
4. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
5. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
6. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA. 1997;277:1305-1307.
7. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
8. Schoni R, Quehenberger P, Wu JR, et al. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA. Thromb Res. 2007;119:17-26.
9. Antovic A, Blomback M, Bremme K, et al. Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance. J Thromb Haemost. 2003;1:2531-2535.
10. Schoni R. The use of snake venom-derived compounds for new functional diagnostic test kits in the field of haemostasis. Pathophysiol Haemost Thromb. 2005;34:234-240.
11. Precision BioLogic. Cryocheck APCR Clot-Based Screening Assay: Clot APCR [package insert]. Dartmouth, Canada: Precision BioLogic; 2007. Insert I-035; Revision 04.
12. Hirsch DR, Mikkola KM, Marks PW, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J. 1996;131:1145-1148.
13. Montes MA, Fox EA, Longtine JA, et al. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients. Arch Pathol Lab Med. 1998;122:325-329.
14. Hall JG, Eis PS, Law SM, et al. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. Proc Natl Acad Sci U S A. 2000;97:8272-8277.
15. Olivier M. The Invader assay for SNP genotyping. Mutat Res. 2005;573:103-110.
16. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003;16:153-168.
17. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-462.
18. Goodman LS, Gilman A, Hardman JG, et al, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill Health Professions Division; 1996.
19. Mueller RL, Scheidt S. History of drugs for thrombotic disease: discovery, development, and directions for the future. Circulation. 1994;89:432-449.
20. Nicolaes GA, Dahlback B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol. 2002;22:530-538.
21. Colman RW. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
22. Biswas A, Bajaj J, Ranjan R, et al. Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis? Clin Chim Acta. 2008;392:21-24.